Metabolism of Piromidic Acid, a New Antibacterial Agent. V. Pharmacokinetics of Piromidic Acid in Humans
スポンサーリンク
概要
- 論文の詳細を見る
The pharmacokinetic studies of piromidic acid (PA, 5,8-dihydro-8-ethyl-5-oxo-2-pyrrolidinopyrido [2,3-d] pyrimidine-6-carboxylic acid=2-pyrrolidino-PPA) were performed in human subjects after oral administration. A compartment model involved thirteen parameters was adopted, in which PA compartment was connected to each compartment in branched metabolic pathway. Each parameter was determined by mathematical method, and a trial and error procedure using the experimental data on blood levels and urinary excretion in man receiving oral PA. Calculated urinary excretion of PA or its metabolites was found to be reasonable. Combined amounts calculated for biological active materials, PA, M-II (2-(2-hydroxypyrrolidino)-PPA) and M-V (2-(3-hydroxypyrrolidino)-PPA) were found to be in good agreement with those by bioassay, demonstrating that this pharmacokinetic model is valid to lead to better understanding of chemotherapeutic effect of PA.
- 公益社団法人日本薬学会の論文
- 1977-09-25
著者
-
橋本 昌久
大日本製薬株式会社総合研究所
-
橋本 昌久
Research Laboratories, Dainippon Pharmaceutical Co., Ltd.,
-
中村 清
Research And Development Division Dainippon Pharmaceutical Co. Ltd.
-
橋本 昌久
Research Laboratories Dainippon Pharmaceutical Co. Ltd.
-
関根 豊
Research and Development Division, Dainippon Pharmaceutical Co., Ltd.
-
宮本 美枝
Research and Development Division, Dainippon Pharmaceutical Co., Ltd.
-
関根 豊
Department of Drug Metabolism, Research Laboratories, Dainippon Pharmaceutical Co., Ltd.,
-
関根 豊
Department Of Drug Metabolism Research Laboratories Dainippon Pharmaceutical Co. Ltd.
-
宮本 美枝
Research And Development Division Dainippon Pharmaceutical Co. Ltd.
関連論文
- マウスおよびラットにおけるLoperamide Hydrochlorideの身体依存性
- Binding of Sulfonamides to Erythrocyte Proteins and Possible Drug-Drug Interaction
- The Synthesis of 2-and 4-Alkoxymethylestrogens.
- Binding of Sulfonamides to Erythrocytes and Their Components
- Autoradiographic Evidences on the Perilobular Distribution of Dehydrocorydaline-^C in the Mouse Liver
- Studies on the Metabolism of Sulfadiazine. I. On the Separation and Identification of Excrements in Human Urine after its Oral Administration.
- リスザルの14C-ヒポキサンチン代謝に対するアロプリノ-ルの影響についてのオ-トラジオグラフィ的研究〔英文〕
- モルモット聴器における14C-pipemidic acidの分布
- Antianoxic Effect of Meclofenoxate related to Its Disposition
- Comparative Studies on the Metabolism of β-Dimethylaminoethanol in the Mouse Brain and Liver Following Administration of β-Dimethyl-aminoethanol and Its p-Chlorophenoxyacetate, Meclofenoxate
- Uptake by Brain and Distribution of Radioactivity after Intravenous Administration of ^C-Labelled Meclofenoxate in Mice
- Metabolism of Piromidic Acid, a New Antibacterial Agent. V. Pharmacokinetics of Piromidic Acid in Humans
- Metabolism of Piromidic Acid, a New Antibacterial Agent. IV. Pharmacokinetics of Piromidic Acid in Rats
- Metabolism of Piromidic Acid, a New Antibacterial Agent. III. Determination of Piromidic Acid and Its Metabolites in Blood, Urine and Bile of Rats and Humans
- Metabolism of Piromidic Acid, a New Antibacterial Agent. II. In Vitro Metabolic Pathway of Piromidic Acid in Rats
- A New Route to 2-Methyl-19-norsteroids
- Intestinal Absorption of a β-Adrenergic Blocking Agent Nadolol. III. : Nuclear Magnetic Resonance Spectroscopic Study on Nadolol-Sodium Cholate Micellar Complex and Intestinal Absorption of Nadolol Derivatives in Rats
- Intestinal Absorption of a β-Adrenergic Blocking Agent Nadolol. II. : Mechanism of the Inhibitory Effect on the Intestinal Absorption of Nadolol by Sodium Cholate in Rats
- Intestinal Absorption of β-Adrenergic Blocking Agent Nadolol. I. : Comparison of Absorption Behaivor of Nadolol with Those of Other β-Blocking Agents in Rats
- Studies on the Metabolism of Sulfadiazine. II. Quantitative Separation of Excrements in the Human Urine after Administration of Sulfadiazine
- ウナギにおけるピロミド酸および代謝物の組織内濃度
- A New Method for Human Serum Phenytoin Based on Enzyme Immunoassay
- A Method for the Determination of Human Serum Phenobarbital Based on a Competitive Binding Enzyme-Immunoassay